Metabolomic Analysis of Systemic Sclerosis

University Hospital, Strasbourg, France121 enrolled

Overview

Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years. The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of vascular lesions, by comparing the profiles of SSc beginners (\<3 years) to established forms (\> 3 years). Secondary purposes: * Prognosis: to study the metabolomics profile of SSc when a visceral complication occurs * Diagnosis: to compare the metabolomics profile of SSc to undifferentiated connective tissue disease (UCDT), Raynaud's disease (RD), vascular disease (VD) and healthy controls * Exploratory: to compare the metabolomics profile of blood, urine and skin of SSc patients

Study Type

OBSERVATIONAL

Enrollment

121

Conditions

Scleroderma (Limited and Diffuse)Undifferentiated Connective Tissue Disease Raynaud Disease Vascular Disease Healthy Control Subjects

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: * Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001) * Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998) * Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease * Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke * Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease) Exclusion criteria: * Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001), or with another auto-immune disease * Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998) * Group 3 (Raynaud) : Patients with no Raynaud disease * Group 4 (vascular disease) : Patients with no vascular disease * Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud, or vascular disease)

Locations (4)

CHU

Dijon, France

Hôpitaux privés de Metz

Metz, France

CHU

Reims, France

Hôpitaux Universitaires de Strasbourg

Strasbourg, France

Outcomes

Primary Outcomes

change of metabolomics profiles between SSc beginners (<3 years) and SSc established forms (> 3 years) at baseline inclusion.

Metabolomic profiles will be classified in a database and compared.

Time frame: 1 point at patient's inclusion visit

Secondary Outcomes

Study and comparison of discriminating metabolomics profiles for prognosis, diagnosis and exploration of SSc.

Metabolomic profiles will be classified in a database and compared between each other's (SSc, UCDT, RD, VD and healthy control arms) We will look for a correlation between these profiles and the evolution of clinical and biological characteristics of SSc (SSc arm)

Time frame: 1st point at patient's inclusion visit (all arms) + 2nd point at patient's complication (group1) during 3 years